Elusive Therapeutic Effect of PCSK9 Inhibitors on Lipoprotein(a) Levels
Author:
Affiliation:
1. Lipoapheresis Unit ‐ Reference Center for Diagnosis and Treatment of Inherited Dyslipidemias Pisa Italy
2. Bioengineering DepartmentFondazione Toscana “Gabriele Monasterio” Pisa Italy
Publisher
Wiley
Subject
Nephrology,Hematology
Link
https://onlinelibrary.wiley.com/doi/pdf/10.1111/1744-9987.12766
Reference7 articles.
1. A Test in Context: Lipoprotein(a)
2. Reduction in Lipoprotein(a) With PCSK9 Monoclonal Antibody Evolocumab (AMG 145)
3. Effect of Alirocumab, a Monoclonal Proprotein Convertase Subtilisin/Kexin 9 Antibody, on Lipoprotein(a) Concentrations (a Pooled Analysis of 150 mg Every Two Weeks Dosing from Phase 2 Trials)
4. Discordant response of low-density lipoprotein cholesterol and lipoprotein(a) levels to monoclonal antibodies targeting proprotein convertase subtilisin/kexin type 9
5. Alirocumab in patients with heterozygous familial hypercholesterolaemia undergoing lipoprotein apheresis: the ODYSSEY ESCAPE trial
Cited by 11 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. Lipoprotein apheresis reduces major adverse cardiovascular event incidence in high-lipoprotein (a) subjects on proprotein convertase subtilisin/kexin type 9 inhibitor therapy;European Journal of Preventive Cardiology;2024-03-12
2. Major cardiovascular events increase in long-term proprotein convertase subtilisin/kexin type 9 inhibitors therapy: the Tuscany cost-effective study;Journal of Cardiovascular Medicine;2023-09-29
3. Alirocumab in lipoprotein apheresis: A synergy for patients with high-Lp(a);Transfusion and Apheresis Science;2023-06
4. Lipoprotein apheresis improves intima media thickness regression: Evidence in the era of new lipid-lowering therapies;Transfusion and Apheresis Science;2023-02
5. Is treating severe He FH so easy? A combined treatment between lipoprotein apheresis and PCSK9 inhibitors;Transfusion and Apheresis Science;2021-12
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3